Next-generation Lyme Disease treatments and vaccines continue to be in high demand in Europe and the U.S. As the geographic footprint of this vector-borne illness widens, it is estimated that 476,000 people in the U.S. and 130,000 people in Europe are impacted each year.
Recent news announced by New York-based Pfizer Inc. and France-based Valneva SE confirmed their investigational Lyme disease vaccine candidate VLA15 is progressing with a late-stage clinical trial.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
